iPSC-Derived Cardiomyocytes for Disease-Specific Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for studying cardiac disorders, such as dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy, face challenges due to species differences between mouse models and humans, limited availability and longevity of cardiac tissues from patients, and the need for effective drug screening tools that provide biologically relevant information with high throughput.
Innovation Solution
The use of induced human pluripotent stem cells (iPS cells) to differentiate into disease-relevant cardiomyocytes, which can be used in vitro or in animal models, allowing for the creation of panels of cardiomyocytes with specific mutations associated with cardiac diseases to test candidate agents and determine their effects on morphologic, genetic, or functional parameters.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mouse models are used to study cardiac disorders, then research can be conducted with available animal models, but species differences reduce the biological relevance and applicability to human disease
Solution Approach 1:
The patent creates human cardiomyocytes by reprogramming human somatic cells into iPSCs and differentiating them into cardiomyocytes. This copies human cardiac tissue in vitro, eliminating species differences while maintaining disease-relevant phenotypes. The human iPSC-derived cardiomyocytes provide biologically relevant data that directly applies to human disease mechanisms and drug responses.
2Reliability
If cardiac tissues from DCM patients are obtained for study, then direct human disease models are created, but the tissues are difficult to obtain and do not survive in long-term culture
Solution Approach 1:
The patent performs preliminary reprogramming of patient somatic cells into iPSCs before differentiation into cardiomyocytes. This preliminary action creates a self-renewing cell population that can be expanded and maintained indefinitely in culture. The iPSC intermediate state preserves the patient's genetic disease profile while enabling long-term culture and multiple passages, solving the short survival time limitation of direct patient cardiac tissues.
3Productivity
If traditional screening programs are used to test candidate compounds, then high throughput can be achieved, but the percentages of hits are very low due to lack of biologically relevant information
Solution Approach 1:
The patent uses patient-specific iPSC-derived cardiomyocytes that express disease-specific phenotypes and molecular characteristics. This local quality - the disease-relevant molecular and cellular properties - enhances the accuracy of hit identification. The screening assay detects compounds that specifically address the disease mechanism in human cardiomyocytes, increasing the percentage of true hits while maintaining high throughput capability.
Data Source
AI summary
Human somatic cells obtained from individuals with a genetic heart condition are reprogrammed to become induced pluripotent stem cells (iPS cells), and differentiated into cardiomyocytes for use in analysis, screening programs, and the like.